Education
About Us
Working with TipRanks
Follow Us
Cannapharmarx Inc (CPMD)
OTHER OTC:CPMD
Top Page
Cannapharmarx
(OTC:CPMD)
Rating:17Underperform
Price Target:―
Cannapharmarx (CPMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.25M
Dividend YieldN/A
Average Volume (3M)217.46K
Price to Earnings (P/E)5.9
Beta (1Y)-4493.25
Revenue GrowthN/A
EPS Growth-797.73%
CountryUS
Employees26
SectorHealthcare
Sector Strength40
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding662,501,400
10 Day Avg. Volume406,105
30 Day Avg. Volume217,458
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-0.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cannapharmarx Business Overview & Revenue Model
Company DescriptionCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
How the Company Makes MoneyCannaPharmaRx makes money through the cultivation and sale of cannabis products. The company's revenue model is based on the production of cannabis in its owned and managed facilities, which is then sold in both medical and recreational cannabis markets. Key revenue streams include wholesale distribution to licensed dispensaries and partnerships with other cannabis brands for product development and distribution. The company may also generate income through strategic partnerships and joint ventures that expand its market reach and optimize its production capabilities.
Cannapharmarx Financial Statement Overview
Summary
Cannapharmarx is facing significant financial challenges, including operational inefficiencies, high leverage, and liquidity constraints. The company has negative stockholders' equity and relies heavily on financing to maintain liquidity, which is unsustainable.Income Statement
The company has experienced significant volatility in its profitability metrics. Despite a positive net income in the latest TTM (Trailing-Twelve-Months), there are substantial negative values in gross profit, EBIT, and EBITDA, indicating ongoing operational challenges. The lack of revenue in previous periods also suggests a potential for inconsistent revenue streams.35
Negative
Balance Sheet
The balance sheet reflects high financial leverage, with a negative stockholders' equity and a debt-to-equity ratio that cannot be calculated due to negative equity. The company's liabilities exceed its assets significantly, indicating financial instability and potential solvency issues.25
Negative
Cash Flow
Cash flow analysis shows negative operating and free cash flows, pointing to challenges in generating cash from operations. The company relies heavily on financing activities to maintain liquidity, which may not be sustainable in the long term.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 338.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | |||||
| -880.83K | -65.56K | -294.93K | -14.36K | -128.50K | -129.03K |
| EBIT | |||||
| -1.76M | -1.58M | -5.21M | -2.99M | -14.49M | -15.98M |
| EBITDA | |||||
| -8.61M | -1.45M | -4.91M | -2.61M | -17.47M | -2.85M |
| Net Income Common Stockholders | |||||
| 1.38M | 3.69M | -8.53M | -10.34M | -22.18M | -24.92M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| -3.66K | 650.00 | 2.32K | 27.77K | 334.97K | 1.55K |
| Total Assets | |||||
| 0.00 | 11.75M | 5.41M | 114.33K | 8.75M | 16.02M |
| Total Debt | |||||
| 314.69K | 12.94M | 14.52M | 9.02M | 10.00M | 9.28M |
| Net Debt | |||||
| 318.35K | 12.93M | 14.52M | 8.99M | 9.67M | 9.28M |
| Total Liabilities | |||||
| 592.63K | 23.90M | 22.76M | 13.04M | 17.55M | 11.16M |
| Stockholders Equity | |||||
| -592.63K | -12.15M | -17.34M | -12.93M | -8.80M | 4.85M |
| Cash Flow | Free Cash Flow | ||||
| -2.82M | -2.36M | -1.56M | -2.42M | -563.57K | -3.84M |
| Operating Cash Flow | |||||
| -2.82M | -2.27M | -1.45M | -2.41M | -563.57K | -3.79M |
| Investing Cash Flow | |||||
| -1.75K | -80.63K | -116.00K | 493.62K | 0.00 | -46.94K |
| Financing Cash Flow | |||||
| 2.83M | 2.35M | 1.40M | 1.30M | 824.57K | 3.27M |
Cannapharmarx Risk Analysis
Cannapharmarx disclosed 63 risk factors in its most recent earnings report. Cannapharmarx reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
While a major part of our business strategy is to pursue strategic acquisitions, we may not be able to identify businesses for which we can obtain necessary financing to acquire on acceptable terms, face risks due to additional indebtedness, and our acquisition strategy may incur significant costs or expose us to substantial risks inherent in the acquired business's operations. Q4, 2022
2.
We may not be able to protect intellectual property that we hope to acquire, which could adversely affect our business. Q4, 2022
Cannapharmarx Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
42 Neutral | $3.54M | ― | -141.39% | ― | -58.46% | 47.98% | |
32 Underperform | $1.92M | ― | -346.19% | ― | ― | -7.18% | |
29 Underperform | $2.70M | ― | -200.56% | ― | ― | 81.35% | |
27 Underperform | $2.37M | ― | -143.99% | ― | -64.77% | 43.53% | |
17 Underperform | $3.25M | 5.88 | -8.32% | ― | ― | -797.73% | |
| $1.22M | ― | -2407.84% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CPMD
Cannapharmarx
0.01
0.00
0.00%
APDN
Applied DNA Sciences
0.53
-29.47
-98.23%
PTPI
Petros Pharmaceuticals
0.03
-15.31
-99.80%
HCTI
Healthcare Triangle
0.04
-0.65
-94.20%
BJDX
Bluejay Diagnostics
1.67
-210.29
-99.21%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.17
-3.38
-95.21%
Cannapharmarx Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Cannapharmarx Appoints Constantine Nkafu as Interim CEO
Neutral
Mar 31, 2025
Cannapharmarx has appointed Constantine Nkafu as the interim CEO, who has been managing the company’s operations for several months. Nkafu, who also serves as the CEO of a subsidiary, brings extensive experience in the pharmaceutical, cannabis, and medical device industries, and has been instrumental in setting up and running complex operations. In addition, the company has appointed Amir Tal, Constantine Nkafu, and Elliot Zemel to its Board of Directors as part of an agreement with LTB Management, LLC. Nkafu and Zemel, both authorized by Health Canada to serve as directors, bring significant expertise and networks in the cannabis industry, which could enhance the company’s strategic positioning.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.